Rituximab (anti-CD 20) is currently undergoing trials for AS. My sparse googling just now shows that rituximab probably only has a moderate effect, so probably second-line to anti-TNFa therapy. Probably.
Safe to say for boards that AS: TNFa > CD20
Monoclonal Antibodies are always last resort! I just use this as a general rule
yMan mttnyaoenuiuotamr/fulimoama ciin,tdnoso uldnignci olnynikgas ssytliiodpn, ear ttarede tiwh RDsMAD ikel hanaFNat-iTp-l aniiemcdots wnhe demrli sfutf edo’stn do eth .crkit oCommn asmxeelp rae aiiilmxbnf dcmei)(Rae adn lmbaumiaad r(ua.Hmi)